Serum EpCAM expression in pancreatic cancer
Standard
Serum EpCAM expression in pancreatic cancer. / Gebauer, Florian; Struck, Lea; Tachezy, Michael; Vashist, Yogesh; Wicklein, Daniel; Schumacher, Udo; Izbicki, Jakob R; Bockhorn, Maximilian.
In: ANTICANCER RES, Vol. 34, No. 9, 01.09.2014, p. 4741-4746.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Serum EpCAM expression in pancreatic cancer
AU - Gebauer, Florian
AU - Struck, Lea
AU - Tachezy, Michael
AU - Vashist, Yogesh
AU - Wicklein, Daniel
AU - Schumacher, Udo
AU - Izbicki, Jakob R
AU - Bockhorn, Maximilian
N1 - Copyright© 2014 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.
PY - 2014/9/1
Y1 - 2014/9/1
N2 - BACKGROUND: Aim of the study was to assess the diagnostic and prognostic impact of serum EpCAM levels in patients with pancreatic adenocarcinoma (PDAC).MATERIALS AND METHODS: For quantitative measurement of preoperative serum EpCAM levels, a sandwich enzyme immunoassay kit was used (ELISA). Sixty-six patients with PDAC were included in the study and for comparison 43 patients with chronic pancreatitis and 104 healthy blood donors without any clinical evidence of cancer were analyzed as well.RESULTS: Serum EpCAM levels differed significantly between the groups. The average value for patients with PDAC was 0.240±0.833 ng/ml, in patients with CP 0.192±0.590 ng/ml and 0.626±1.164 ng/ml in normal blood donor sera. With a cut-off level of 0.422 ng/ml EpCAM, the calculated sensitivity of detecting PDAC was 66.7% with corresponding specificity of 77.5%. A correlation with clinico-pathological data (pT, pN, M, R-status, grading, UICC stage) was not found and in addition there was no difference in overall survival between patients with high- and low-preoperative serum EpCAM levels.CONCLUSION: EpCAM can be detected in the serum in patients with PDAC though the sensitivity for detecting PDAC is low and a correlation with clinical parameters was not found.
AB - BACKGROUND: Aim of the study was to assess the diagnostic and prognostic impact of serum EpCAM levels in patients with pancreatic adenocarcinoma (PDAC).MATERIALS AND METHODS: For quantitative measurement of preoperative serum EpCAM levels, a sandwich enzyme immunoassay kit was used (ELISA). Sixty-six patients with PDAC were included in the study and for comparison 43 patients with chronic pancreatitis and 104 healthy blood donors without any clinical evidence of cancer were analyzed as well.RESULTS: Serum EpCAM levels differed significantly between the groups. The average value for patients with PDAC was 0.240±0.833 ng/ml, in patients with CP 0.192±0.590 ng/ml and 0.626±1.164 ng/ml in normal blood donor sera. With a cut-off level of 0.422 ng/ml EpCAM, the calculated sensitivity of detecting PDAC was 66.7% with corresponding specificity of 77.5%. A correlation with clinico-pathological data (pT, pN, M, R-status, grading, UICC stage) was not found and in addition there was no difference in overall survival between patients with high- and low-preoperative serum EpCAM levels.CONCLUSION: EpCAM can be detected in the serum in patients with PDAC though the sensitivity for detecting PDAC is low and a correlation with clinical parameters was not found.
KW - Adult
KW - Aged
KW - Antigens, Neoplasm
KW - Carcinoma, Pancreatic Ductal
KW - Cell Adhesion Molecules
KW - Female
KW - Follow-Up Studies
KW - Humans
KW - Male
KW - Middle Aged
KW - Neoplasm Grading
KW - Neoplasm Staging
KW - Pancreatic Neoplasms
KW - Prognosis
KW - Sensitivity and Specificity
KW - Tumor Markers, Biological
M3 - SCORING: Journal article
C2 - 25202052
VL - 34
SP - 4741
EP - 4746
JO - ANTICANCER RES
JF - ANTICANCER RES
SN - 0250-7005
IS - 9
ER -
